Drug - Erwinaze (asparaginase Erwinia chryanthemi) [EUSA Pharma, Inc]
June 2012
Therapeutic area - Oncology
E. coli-derived asparaginse products include Elspar (asparaginase) and Oncaspar (peg-asparagase).
NCCN guidelines recommend that patients who develop severe hypersensitivity reactions during treatment with E. coli asparaginase stop current therapy with the offending agent and switch to Erwinaze.
MHCP Provider Call Center 651-431-2700 or 800-366-5411